Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

Investors may be wary of Glenmark Pharmaceuticals Limited as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 22.730759
debtToEquity 21.086000
earningsGrowth 0.000000
revenueGrowth 0.351000
grossMargins 0.683010
operatingMargins 0.140950
trailingEps -7.090000
forwardEps 42.480000

GLENMARK's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
GLENMARK's low Debt-to-Equity ratio reflects the company's conservative use of debt. This shows that it isn't over-leveraged, reducing financial risk and indicating a stable financial structure, which is a positive signal for investors concerned about excessive debt burdens.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

Over time, price projections for Glenmark Pharmaceuticals Limited have gradually increased, reflecting rising confidence in the company's future performance. This upward trend suggests analysts expect Glenmark Pharmaceuticals Limited to continue on a positive growth trajectory.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


Analysts have maintained a buy bias for GLENMARK, which could prompt investors to consider the stock as a viable investment. With this positive outlook, GLENMARK is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.